Verisante Named Edison Awards Finalist

Verisante Named Edison Awards Finalist 
Aura to Be Recognized at Edison Awards Gala on April 25, 2013 in
Chicago 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/13/13 -- Verisante
Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that Verisante Aura(TM), a revolutionary skin cancer
detection device, has been named a 2013 finalist by the
internationally renowned Edison Awards(TM). The distinguished awards
symbolize the persistence and excellence personified by Thomas Alva
Edison, inspiring creative minds to remain in the forefront of
innovation, creativity and ingenuity in the global economy. 
"More than we have seen at any other time previously, this year's
slate of finalists demonstrate the enormous value of teamwork,
experimentation, consumer focus, market awareness and game-changing
success," said Frank Bonafilia, Edison Awards' executive director.
"It's exciting to see companies like Verisante continuing Thomas
Edison's legacy of challenging conventional thinking."  
"It is an honour to be selected as an Edison Awards finalist," said
Thomas Braun, President & CEO of Verisante. "Aura(TM) is a
game-changing innovation that will significantly improve patient
outcomes and care. It has taken some of the field's brightest minds
and years of research and commitment to bring this technology to
commercialization." 
The ballot of nominees for the Edison Awards is judged by more than
3,000 senior business executives and academics from across the nation
whose votes acknowledge the finalists' success in meeting the award
criteria of Concept, Value, Delivery and Impact. The panel includes
members of the Marketing Executives Networking Group (MENG), the
American Association Advertising Agencies (4As), the Chief Marketing
Officer Council (CMO), the Design Management Institute (DMI), the
American Productivity & Quality Center (APQC), the American Society
of Mechanical Engineers (ASME) and the Association of Technology
Management & Applied Engineering (ATMAE). Also on the panel are
hundreds of past Edison Award winners, marketing professionals,
scientists, designers, engineers and academics. 
Award winners will be announced April 25, 2013 at the Edison Awards
Annual Gala,
 held in the Grand Ballroom at historic Navy Pier in
Chicago, IL.  
About the Edison Awards 
The Edison Awards is a program conducted by Edison Universe, a
501(c)(3) charitable organization dedicated to fostering future
innovators. The 2013 Edison Awards are sponsored by Nielsen,
Discovery Communications, Science Channel, and USA Today. For more
information about the Edison Awards, Edison Universe and a list of
past winners, visit www.edisonawards.com. 
About Verisante Technology, Inc. 
Verisante is a medical device company committed to commercializing
innovative systems for the early detection of cancer. The Verisante
Aura(TM) for skin cancer detection and the Verisante Core(TM) series
for lung, colon and cervical cancer detection utilize a proprietary
cancer detection platform while the operating software and probe
technology are unique to each device. The cancer detection platform
was developed by the BC Cancer Agency and tested and refined at the
Skin Care Centre at Vancouver General Hospital. This exclusive
platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians
immediate results for many of the most common cancers. Aura(TM) has
been approved for sale in Canada, Europe and Australia. The Core(TM)
has not yet been approved for sale.  
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of
What's New 
Award" for 2011, and awarded a 2013 Prism Award for
Innovation in Photonics. Verisante Core(TM) was named one of the top
10 cancer breakthroughs of 2011 by the Canadian Cancer Society.  
Website: www.verisante.com 
Youtube: www.youtube.com/verisante 
Twitter: www.twitter.com/verisante 
Facebook: www.facebook.com/verisante 
Forward Looking Statements  
This release contains forward-looking statements, including, but not
limited to, statements regarding the future commercialization of
medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks, and
the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. 
The TSX Venture Exchange has neither approved nor disapproved of the
contents of this press release. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release. 
Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com